Payment overview · 2025
General Payments
$91.74
5 reported records · 3 companies
Healthcare provider profile · identity verified
Harrison Marshall Lief, MD
Allopathic & Osteopathic Physicians|Internal Medicine · THE VILLAGES, FL · NPI 1174027387
Verified facts
What the public records show
CMS Open Payments records show Harrison Marshall Lief, MD received $91.74 in general payments during 2025 across 5 reported records.
GlaxoSmithKline, LLC. accounted for 60.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.16 | 60.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.00 | 21.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.58 | 18.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.74 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.16 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 574 | 198 |
| Lisinopril | Lisinopril | 495 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 482 | 156 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 360 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 119 |
| Gabapentin | Gabapentin | 348 | 137 |
| Losartan Potassium | Losartan Potassium | 321 | 103 |
| Omeprazole | Omeprazole | 306 | 100 |
| Metformin Hcl | Metformin Hcl | 305 | 91 |
| Trazodone Hcl | Trazodone Hcl | 247 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 78 |
| Alprazolam | Alprazolam | 230 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 223 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 212 | 67 |
| Furosemide | Furosemide | 205 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 65 |
| Tramadol Hcl | Tramadol Hcl | 201 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 60 |
| Simvastatin | Simvastatin | 178 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 67 |
| Montelukast Sodium | Montelukast Sodium | 170 | 63 |
| Famotidine | Famotidine | 165 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 162 | 51 |
| Methylprednisolone | Methylprednisolone | 154 | 105 |
| Glimepiride | Glimepiride | 143 | 51 |
| Pregabalin | Pregabalin | 140 | 43 |
| Carvedilol | Carvedilol | 138 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 130 | 101 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 48 |
| Azithromycin | Azithromycin | 121 | 86 |
| Meloxicam | Meloxicam | 118 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 31 |
| Sertraline Hcl | Sertraline Hcl | 111 | 35 |
| Mirtazapine | Mirtazapine | 109 | 43 |
| Ozempic | Semaglutide | 107 | 28 |
| Eliquis | Apixaban | 103 | 37 |
| Allopurinol | Allopurinol | 102 | 38 |
| Potassium Chloride | Potassium Chloride | 102 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 65 |
| Ezetimibe | Ezetimibe | 98 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 90 | 35 |
| Alendronate Sodium | Alendronate Sodium | 89 | 31 |
| Finasteride | Finasteride | 88 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 35 |
| Glipizide | Glipizide | 86 | 29 |
| Clonidine Hcl | Clonidine Hcl | 84 | 24 |
| Clotrimazole | Clotrimazole | 80 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 22 |
| Fenofibrate | Fenofibrate | 69 | 22 |
| Clonazepam | Clonazepam | 68 | 14 |
| Atenolol | Atenolol | 67 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 27 |
| Buspirone Hcl | Buspirone Hcl | 61 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 47 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 32 |
| Ibuprofen | Ibuprofen | 61 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 19 |
| Mounjaro | Tirzepatide | 57 | 17 |
| Acyclovir | Acyclovir | 56 | 19 |
| Jardiance | Empagliflozin | 56 | 21 |
| Meclizine Hcl | Meclizine Hcl | 56 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 26 |
| Baclofen | Baclofen | 51 | 21 |
| Cephalexin | Cephalexin | 51 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 17 |
| Trulicity | Dulaglutide | 51 | 16 |
| Fluconazole | Fluconazole | 50 | 29 |
| Donepezil Hcl | Donepezil Hcl | 49 | 19 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Spironolactone | Spironolactone | 49 | 17 |
| Ketoconazole | Ketoconazole | 48 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 14 |
| Lidocaine | Lidocaine | 43 | suppressed |
| Prednisone | Prednisone | 43 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 15 |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Glipizide Er | Glipizide | 39 | 13 |
| Methocarbamol | Methocarbamol | 39 | 14 |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 19 |
| Temazepam | Temazepam | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 23 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Ofloxacin | Ofloxacin | 31 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 15 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | 11 |
| Metformin Hcl Er | Metformin Hcl | 26 | 11 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Metronidazole | Metronidazole | 24 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 15 |
| Nystatin | Nystatin | 23 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.74 · 5 records | GlaxoSmithKline, LLC. | FREESTYLE LIBRE 3, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error